Article Text

Download PDFPDF
Critical analysis of the effect the new Medical Device Regulation will have on the relevant stakeholder
  1. Tehzeem Ahmed1,2,3,
  2. Junaid Zafar4,
  3. Faisal Sharif1,2,5,6,
  4. Haroon Zafar1,2
  1. 1 Cardiovascular Translational Research and Innovation Centre, National University of Ireland Galway, Galway, Ireland
  2. 2 Lambe Institute for Translational Research, School of Medicine, National University of Ireland Galway, Galway, Ireland
  3. 3 School of Law, National University of Ireland Galway, Galway, Ireland
  4. 4 Faculty of Engineering, Government College University Lahore, Lahore, Pakistan
  5. 5 Department of Cardiology, University Hospital Galway, Galway, Ireland
  6. 6 CÚRAM-SFI Centre for Research in Medical Devices, National University of Ireland Galway, Galway, Ireland
  1. Correspondence to Dr Haroon Zafar, National University of Ireland Galway, Galway, Ireland; haroon.zafar{at}


The regulatory framework around medical devices in the European Union has always focused on upholding patient safety. However, over the years, certain scandals have come to light in which patient safety has been compromised considerably. As a consequence, the overwhelming opprobrium was the cause for a radical change. The new Medical Device Regulation (MDR) has now been introduced (but yet to be fully implemented) to primarily combat the issues that have arisen as a result of these scandals. The MDR has been subject to significant commentary, particularly the effect it will have on relevant stakeholders. The stakeholders in the context of the MDR are the manufacturers, distributors, authorised representatives and importers. There is a general consensus among various professionals that the new requirements are far more onerous than the obligations contained in the previous regulatory framework. Moreover, there has been a lengthy delay in the date of application for the MDR. In particular, the approval of the notified bodies is raising a great concern. This paper will provide a critical analysis of the new requirements that stakeholders must comply with and, in addition, will review the postponement of the MDR.

  • cardiology
  • health care quality, access, and evaluation
  • health

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors TA and HZ planned the study. TA, JZ and HZ conducted the search and analysis. All authors contributed to the writing of the paper.

  • Funding HZ is supported by the Science Foundation Ireland Technology Innovation Development Award (grant number 18/TIDA/6017) and the Irish Research Council New Foundations Grant 2020.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.